MedTrace Logo

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

NCT00369265 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-08-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Lansoprazole 30mg taken twice daily is effective in the treatment of laryngitis due to gastroesophageal reflux.

Conditions

  • Laryngopharyngeal Reflux

Interventions

DRUG

Lansoprazole

Lansoprazole 30mg twice daily

DIETARY_SUPPLEMENT

Sugar pill

placebo twice daily

Sponsors & Collaborators

  • American Institute for Voice and Ear Research

    lead OTHER

Principal Investigators

  • Robert T Sataloff, MD, DMA · American Institute for Voice and Ear Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369265 on ClinicalTrials.gov